

How can I learn more about STEADY-PD III?

To learn more about this study, please visit <http://www.STEADYPD3.com>, <http://www.clinicaltrials.gov> or call 1-855-825-3390.

If you would like more information about STEADY-PD III, please contact

Please place your contact sticker here [Site PI] [Site Coordinator]

Participating Site Locations in the US and Canada:

US

Birmingham, AL	Las Vegas, NV
Sun City, AZ	Albany, NY
Fountain Valley, CA	Kingston, NY
Irvine, CA	Manhasset, NY
La Jolla, CA	New York, NY
San Francisco, CA	Rochester, NY
Sunnyvale, CA	Cincinnati, OH
Englewood, CO	Cleveland, OH
Manchester, CT	Columbus, OH
New Haven, CT	Portland, OR
Miami, FL	Hershey, PA
Tampa, FL	Philadelphia, PA
Weston, FL	Charleston, SC
Atlanta, GA	Houston, TX
Honolulu, HI	Salt Lake City, UT
Chicago, IL	Charlottesville, VA
Lexington, KY	Virginia Beach, VA
Shreveport, LA	Kirkland, WA
Boston, MA	Milwaukee, WI
Baltimore, MD	
Ann Arbor, MI	
East Lansing, MI	
Golden Valley, MN	
Minneapolis, MN	
St Louis, MO	
Omaha, NE	
Lebanon, NH	
Summit, NJ	

Canada

Calgary, AB
Edmonton, AB
London, ON
Markham, ON
Ottawa, ON
Toronto, ON
Montreal, QC
Quebec City, QC

About the Parkinson Study Group

The Parkinson Study Group (PSG) is a non-profit group of physicians and other health care providers from medical centers in the United States and Canada, experienced in the care of Parkinson patients and dedicated to clinical research of Parkinson disease (PD). The PSG was formed in 1986, prompted by the recognition that clinical research in PD required the participation of large numbers of research patients (subjects) under the cooperative care of skilled and experienced research physicians.

The PSG aims to advance knowledge about the causes, disease progression and treatment of PD and related disorders. The PSG is committed to:

- open communication within the scientific community
- ensuring research is fully reviewed by other health care providers prior to publication to make certain that all research results (good and bad) are available to the public
- revealing all potential conflicts of interest of the group and each PSG member and
- democratic governance of its organizations and activities.

STEADY PD III Steering Committee

Tanya Simuni, MD
Principal Investigator

Kevin Biglan, MD, MPH
Co-Principal Investigator

RSRB-University of Rochester-Approval
RSRB No. 50648
Expires January 7, 2015
- j1 6/22/14 -

STEADY-PD III



Efficacy of Isradipine in early Parkinson Disease

PSG
PARKINSON STUDY GROUP

A clinical trial conducted by the PSG funded by a grant from the National Institute of Neurological Disorders and Stroke.



National Institute of
Neurological Disorders
and Stroke